The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto’s thyroiditis: An immunohistochemical characterization

European Journal of Histochemistry

Volumn 54, Issue 2, 2010, Pages 118-122

  Ruggeri, R M ^a   Vitarelli, E ^b   Barresi, G ^b   Trimarchi, F ^a   Benvenga, S ^a   Trovato, Maria ^b  

^a Unit of Endocrinology   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Hashimoto s thyroiditis; HGF c met signaling; PI3K; RHO; Thyroid nodules

Indexed keywords

EID: 84995684251     PISSN: 1121760X     EISSN: 20388306     Source Type: Journal    
DOI: 10.4081/ejh.2010.e24     Document Type: Article

References (39)

1. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003;148:1-9.
2. Weetman AP. Autoimmune thyroid disease. Autoimmunity 2004;37:337-40.
3. Rago T, Chiovato L, Grasso L, Pinchera A, Vitti P. Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects. J Endocrinol Invest 2001; 24:763-9.
4. Ruggeri RM, Sciacchitano S, Trimarchi F, Barresi G, Trovato M. Expression of hepatocyte growth factor in Hashimoto's thyroiditis with nodular lesions. Eur J Histochem 2007;51:193-8.
5. Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in North- Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid 2008;18:429-41.
6. Ruggeri RM, Sciacchitano S, Vitale A, Cardelli P, Galletti M, Vitarelli E et al. Serum Hepatocyte Growth Factor (HGF) is increased in Hashimoto’s thyroiditis either or nor associated with nodular goiter as compared with healthy non-goitrous individuals. J Endocrinol Invest 2009;32: 465-9.
7. Bidey SP, Hill DJ, Eggo MC. Growth factors and goitrogenesis. J Endocrinol 1999;160: 321-32.
8. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56.
9. Eggo MC, Quiney VM, Campbell S. Local factors regulating growth and function of human thyroid cells in vitro and in vivo. Mol Cell Endocrinol 2003;213:47-58.
10. Ruggeri RM, Villari D, Simone A, Scarfì R, Attard M, Orlandi F et al. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J Endocrinol Invest 2002;25:959-66.
11. Ruggeri RM, Barresi G, Sciacchitano S, Trimarchi F, Benvenga S, Trovato M. Immuno expression of the CD30 ligand/ CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases. Histol Histopathol 2006;21:249-56.
12. Bottaro DP, Rubin JS, Faletto D, Chan AM, Kmiecik TE, Vande Woude GF et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
13. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993; 121:145-54.
14. Eccles N, Ivan M, Wynford-Thomas D. Mitogenic stimulation of normal and oncogene transformed human thyroid epithelial cells by hepatocyte growth factor. Mol Cell Endocrinol 1996;117:247-51.
15. Trovato M, Villari D, Bartolone L, Spinella S, Simone A, Violi MA et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 1998;8:125-31.
16. Trovato M, Grosso M, Vitarelli E, Ruggeri RM, Alesci S, Trimarchi F et al. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol 2003;18:393-9.
17. Scarpino S, D'Alena FC, Di Napoli A, Ballarini F, Prat M, Ruco LP. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol 2003; 199:243-50.
18. Mineo R, Costantino A, Frasca F, Sciacca L, Russo S, Vigneri R et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endo crinology 2004;145: 4355-65.
19. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991;266: 22087-90.
20. Ponzetto C, Zhen Z, Audero E, Maina F, Bardelli A, Basile ML et al. Specific uncoupling of GRB2 from the met receptor. Differential effects on transformation and motility. J Biol Chem 1996;271:14119-23.
21. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391: 285-8.
22. Okano J, Shiota G, Matsumoto K, Yasui S, Kurimasa A, Hisatome I et al. Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway. Biochem Biophys Res Commun 2003;309: 298-304.
23. Vandeput F, Perpete S, Coulonval K, Lamy F, Dumont JE. Role of the different mitogenactivated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 5'-monophosphate and growth factors. Endocrinology 2003;144:1341-9.
24. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15:1110-22.
25. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/ scatter factor-induced adherens junction disassembly. Mol Biol Cell 1998;9:2185-200.
26. Bardelli A, Basile ML, Audero E, Giordano S, Wennström S, Ménard S et al. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 1999;18:1139-46.
27. Kodama A, Matozaki T, Fukuhara A, Kikyo M, Ichihashi M, Takai Y. Involvement of an SHP- 2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering. Mol Biol Cell 2000; 11:2565-75.
28. Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell 2000;11:1709-25.
29. Coulonval K, Vandeput F, Stein RC, Kozma SC, Lamy F, Dumont JE. Phosphati dylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J 2000;348:351-8.
30. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-Kinase/Akt and mitogen- activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-16.
31. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 2008;37:375-87.
32. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3- kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278-84.
33. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol- 3-kinase/AKT pathway in thyroid tumors. J Clin Endocrinol Metab 2007;92: 2387-90.
34. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto’s thyroiditis and the role of the PI3K/Akt pathway. J Am Coll Surg 2007;204:764-73.
35. Hazeki K, Nigorikawa K, Hazeki O. Role of phosphoinositide 3-kinase in innate immunity. Biol Pharm Bull 2007;30:1617-23.
36. Matheu MP, Deane JA, Parker I, Fruman DA, Cahalan MD. Class IA phosphoinositide 3- kinase modulates basal lymphocyte motility in the lymph node. J Immunol 2007;179: 2261-9.
37. Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007;19:44-8.
38. Li Volsi V. Lymphocytes in the thyroid. In: Li Volsi V. ed. Surgical Pathology of the Thyroid. W.B. Saunders Company, Philadelphia, 1990, PP. 68-97.
39. Trovato M, Ulivieri A, Dominici R, Ruggeri RM, Vitarelli E, Benvenga S et al. Clinicopathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. Endocr Relat Cancer 2004; 11: 365-76.